{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination broadens the displayed antigen repertoire on tumor cells.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
                    "line_ref": "L28"
                },
                {
                    "quote": "Broader antigen display after intratumoral mRNA vaccination",
                    "line_ref": "L28"
                }
            ],
            "caveat": "This finding is from mouse models, and the broadening of the antigen repertoire does not guarantee a therapeutic effect."
        },
        {
            "claim_id": "C02",
            "claim": "mRNA vaccination in the tumor enhances the presentation of peptides on MHC-I.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
                    "line_ref": "L29"
                },
                {
                    "quote": "Strong expansion of MHC-I-presented landscape",
                    "line_ref": "L29"
                }
            ],
            "caveat": "This was observed in murine models and may not directly translate to human tumors."
        },
        {
            "claim_id": "C03",
            "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in human patients treated with ICI.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "Retrospective human survival comparison p-value | p=0.01",
                    "line_ref": "L30"
                },
                {
                    "quote": "Vaccinated subgroup had improved survival under ICI treatment",
                    "line_ref": "L30"
                }
            ],
            "caveat": "The human analysis is retrospective and non-randomized, so residual confounding is a significant threat to validity."
        },
        {
            "claim_id": "C04",
            "claim": "Intratumoral mRNA vaccination induces a strong type I interferon response, which is critical for the sensitization effect.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
                    "line_ref": "L31"
                },
                {
                    "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
                    "line_ref": "L39"
                }
            ],
            "caveat": "This mechanistic link was established in mouse models and requires further validation in humans."
        }
    ]
}